期刊文献+

盐酸安罗替尼联合替吉奥治疗老年进展期非小细胞肺癌的临床疗效观察 被引量:4

Anlotinib hydrochloride combined S 1 in elderly patients with advanced progressive non-small cell lung cancer
下载PDF
导出
摘要 目的观察盐酸安罗替尼联合替吉奥治疗老年进展期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取30例经病理组织学和(或)细胞学检查确诊的表皮生长因子(EGFR)突变阴性老年进展期NSCLC患者为研究对象,予盐酸安罗替尼胶囊联合替吉奥胶囊治疗,连续口服14天,停药7天,21天为1个周期,直至疾病进展或出现不可耐受的不良反应。根据实体瘤疗效评价标准进行疗效评价。结果30例患者中,2例患者失访,其余28例患者中,部分缓解9例,疾病稳定15例,疾病进展4例,客观缓解率为32.1%,疾病控制率为85.7%,中位无进展生存期为6.5个月(95%CI:5.8~7.2个月),中位总生存期为10.5个月(95%CI:8.9~12.1个月)。最常见的不良反应包括骨髓抑制、恶心呕吐、乏力、高血压、手足综合征、皮肤黏膜反应、肝功能异常、肾功能异常、蛋白尿以及腹泻等,所有不良反应经对症治疗后均可缓解。结论盐酸安罗替尼联合替吉奥治疗老年进展期NSCLC患者具有较好的临床疗效,且不良反应可耐受。 Objective To observe the efficacy and safety of anlotinib hydrochloride combined S-1 in elderly patients with advanced progressive non-small cell lung cancer(NSCLC).Method A total of 30 elderly patients with histological-ly and(or)cytologically confirmed epidermal growth factor receptor(EGFR)mutation-negative advanced progressive NSCLC were selected,all patients received anlotinib hydrochloride and S-1 for 14 days with 7 days discontinuation as one cycle(21 days)until disease progression or treatment intolerance.Efficacy was evaluated according to response eval-uation criteria in solid tumor.Result Two patients were lost to follow-up in 30 patients.Among the evaluable 28 pa-tients,9 patients achieved partial response(PR),15 had stable disease(SD)and 4 patients had progressive disease(PD).The objective response rate(ORR)was 32.1%and the disease control rate(DCR)was 85.7%.The median progression free survival(mPFS)and the median overall survival(mOS)were 6.5 months(95%CI:5.8-7.2)and 10.5 months(95%CI:8.9-12.1),respectively.The most common adverse events included bone marrow suppression,nausea and vomiting,fa-tigue,hypertension,hand-foot syndrome,skin and mucous membrane reaction,abnormal liver function,abnormal renal function,proteinuria and diarrhea,all relieved after symptomatic treatment.Conclusion Anlotinib hydrochloride com-bined S-1 has significant therapeutic efficacy in elderly patients with advanced progressive NSCLC and well-tolerated ad-verse events.
作者 王建芳 纪蓉 孙彩萍 陈遐林 WANG Jianfang;JI Rong;SUN Caiping;CHEN Xialin(Department of Oncology,Shaoxing People’s Hospital,Shaoxing 312000,Zhejiang,China;Department of Radiotherapy,Shaoxing Second Hospital,Shaoxing 312000,Zhejiang,China)
出处 《癌症进展》 2022年第3期242-245,共4页 Oncology Progress
基金 浙江省医学会临床科研基金项目(2019ZYC-A47) 绍兴市科技局公益性技术应用研究项目(2018C30096)。
关键词 盐酸安罗替尼 替吉奥 非小细胞肺癌 老年 anlotinib hydrochloride S-1 non-small cell lung cancer elderly
  • 相关文献

参考文献2

二级参考文献21

  • 1Siegel R,Naishadham D, Jemal A. Cancer statistics,2013 [ J]. CA Cancer J Clin, 2013, 63 : 11-30. 被引量:1
  • 2Gridelli C ,Langer C ,Maione P,et al. Lung cancer in the elderly [J]. J Clin Oncol, 2007, 25:1898-1907. 被引量:1
  • 3Vora N, Reckamp KL. Non-small cell lung cancer in the elderly : defining treatment options [ J ]. Semin Oncol, 2008, 35: 590-596. 被引量:1
  • 4Fujisawa T, Yamaguchi Y, Baba M, et al. Recent advances of surgical treatment in elderly lung cancer patient[ J[. Nihon Kyobu Shikkan Gakkai Zasshi, 1992, 30:224-229. 被引量:1
  • 5Bahleda R, Hollebecque A, Varga A, Gazzah A, et al. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer, 2015,76:126-130. 被引量:1
  • 6Ishida T ,Yokoyama H,Kaneko S ,et al. Eong-term results of operation for non-small cell lung cancer in the elderly [ J ]. Ann Thorac Surg, 1990, 50:919-922. 被引量:1
  • 7Ginsberg R J, Rubinstein LV. Randomized trial of lobectomy ver-sus limited resection for T1 NO non-small cell lung cancer. Lung Cancer Study Group[ J ]. Ann Thorac Surg, 1995, 60:615-22 ; discussion 622-623. 被引量:1
  • 8Nakamura H, Kawasaki N, Taguchi M, et al. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-a-nalysis[ J]. Br J Cancer, 2005, 92 : 1033-1037. 被引量:1
  • 9Mery CM,Pappas AN,Bueno R,et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology,and end results database[ J]. Chest, 2012, 128:237-245. 被引量:1
  • 10Chamogeorgakis T, Ieromonaehos C, Georgiannakis E, et al. Does lobeetomy achieve better survival and recurrence rates than limited pulmonary resection for T1NOMO non-small cell lung cancer patients? [ J]. Interact Cardiovasc Thorae Surg, 2009, 8:364-372. 被引量:1

共引文献27

同被引文献54

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部